214 related articles for article (PubMed ID: 17079479)
1. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
El-Rayes BF; Ali S; Ali IF; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2006 Nov; 66(21):10553-9. PubMed ID: 17079479
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Ali S; El-Rayes BF; Sarkar FH; Philip PA
Mol Cancer Ther; 2005 Dec; 4(12):1943-51. PubMed ID: 16373709
[TBL] [Abstract][Full Text] [Related]
3. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Ali S; Banerjee S; Ahmad A; El-Rayes BF; Philip PA; Sarkar FH
Mol Cancer Ther; 2008 Jun; 7(6):1708-19. PubMed ID: 18566242
[TBL] [Abstract][Full Text] [Related]
5. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
7. Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway.
Liang C; Li H; Shen C; Lai J; Shi Z; Liu B; Tao HM
Anticancer Agents Med Chem; 2012 Jun; 12(5):554-63. PubMed ID: 22263786
[TBL] [Abstract][Full Text] [Related]
8. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Gadgeel SM; Ali S; Philip PA; Wozniak A; Sarkar FH
Cancer; 2009 May; 115(10):2165-76. PubMed ID: 19288574
[TBL] [Abstract][Full Text] [Related]
9. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
[TBL] [Abstract][Full Text] [Related]
10. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line.
Mohammad RM; Wang S; Banerjee S; Wu X; Chen J; Sarkar FH
Pancreas; 2005 Nov; 31(4):317-24. PubMed ID: 16258364
[TBL] [Abstract][Full Text] [Related]
11. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
12. Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
Yotsumoto F; Fukami T; Yagi H; Funakoshi A; Yoshizato T; Kuroki M; Miyamoto S
Cancer Sci; 2010 Nov; 101(11):2351-60. PubMed ID: 20726858
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer.
Fahy BN; Schlieman MG; Virudachalam S; Bold RJ
J Am Coll Surg; 2004 Apr; 198(4):591-9. PubMed ID: 15051014
[TBL] [Abstract][Full Text] [Related]
15. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Morgan MA; Parsels LA; Kollar LE; Normolle DP; Maybaum J; Lawrence TS
Clin Cancer Res; 2008 Aug; 14(16):5142-9. PubMed ID: 18698032
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
El-Rayes BF; Philip PA; Sarkar FH; Shields AF; Ferris AM; Hess K; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA; Abbruzzese JL
Invest New Drugs; 2011 Aug; 29(4):694-9. PubMed ID: 20107864
[TBL] [Abstract][Full Text] [Related]
17. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
Torres C; Linares A; Alejandre MJ; Palomino-Morales RJ; Delgado JR; Perales S
Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
[TBL] [Abstract][Full Text] [Related]
18. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
[TBL] [Abstract][Full Text] [Related]
19. Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway.
Liu J; Huang Y; Liu Y; Chen Y
Med Sci Monit; 2019 Aug; 25():6085-6096. PubMed ID: 31412018
[TBL] [Abstract][Full Text] [Related]
20. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]